Yellow Fever
Updated: December 2000
Know before you go!
Infectious diseases not necessarily common in Canada can occur and may even
be widespread in other countries. Standards of hygiene and medical care may
differ from those at home. Before departure, you should learn about the health
conditions in the country or countries you plan to visit, your own risk of
disease and the steps you can take to prevent illness.
The risk is yours
Your risk of acquiring a disease depends on several factors.
They include: your age, gender, immunization status and current state
of health; your itinerary, duration and style of travel (e.g., first
class, adventure) and anticipated travel activities (e.g., animal contact,
exposure to fresh water, sexual contact); as well as the local disease
situation.
Risk assessment consultation
The Public Health Agency of Canada strongly recommends that
your travel plans include contacting a travel medicine clinic or physician
6 to 8 weeks before departure. Based on your individual risk assessment,
a health care professional can determine your need for immunizations
and/or preventive medication (prophylaxis) and advise you on precautions
to avoid disease. We can help you locate a travel
medicine clinic closest to your home.
Some facts from the experts The information below has been developed and is updated in consultation
with Public Health Agency of Canada's Committee
to Advise on Tropical Medicine and Travel (CATMAT). The
recommendations are intended as general advice about the prevention of
measles for Canadians travelling internationally.
Disease profile |

|
Yellow fever is an acute viral infection of short duration and varying
severity. The disease occurs in two forms -- urban and sylvatic (jungle)
yellow fever. Both forms are caused by the same virus, which is a member
of the Flaviviridae family of viruses.
Transmission
Yellow fever is transmitted to humans by the bite of infected
mosquitoes from a variety of species, principally the Aedes and Haemagogus species.
These mosquitoes are day-time biters.
Geographic
distribution |

|
Yellow fever is constantly present (i.e., endemic) in many tropical areas
of South America and Africa. From time to time in endemic areas, the number
of yellow fever cases can increase dramatically to the epidemic level. For
the most part, yellow fever transmission is restricted to rural and jungle
areas.
Table 1: Countries where yellow fever occurs |
Angola
Benin
Bolivia
Brazil
Burkina Faso
Burundi
Cameroon
Central African
Republic
Chad
Colombia
Congo
Côte d'Ivoire
Democratic Republic
of the Congo
(formerly Zaire)
Ecuador
|
Equatorial
Guinea
Ethiopia
French Guiana
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Guyana
Kenya
Liberia
Mali
Niger
Nigeria
Panama
Peru |
Rwanda
Sao Tome &
Principe
Senegal
Sierra Leone
Somalia
Sudan
Suriname
Tanzania, United
Republic of
Togo
Uganda
Venezuela
Zambia |
Source: World Epidemiological Record (WER), vol. 75, No. 41 (Oct.
13, 2000), World Health Organization
|
Symptoms |

| Some infected individuals have no symptoms. When they do occur, symptoms
take 3 to 6 days to appear and range from self-limiting fever to sudden onset
of fever with chills, headache, muscle pain (back pain), loss of appetite,
nausea and/or vomiting. In severe cases, yellow fever can lead to shock, bleeding,
organ failure, jaundice (i.e., yellowing of skin and eyes) and death.
Treatment |

|
There is no specific treatment for yellow fever. The overall case-fatality
rate may reach 20% to 40% in single outbreaks. Deaths from yellow fever have
been reported among unvaccinated travellers. Vaccine
The single-dose 'live' vaccine for yellow fever is safe, effective and
recommended for individuals 9 months of age and older. The vaccine becomes
protective after 10 days, and provides immunity to a vaccinated individual
for 10 years or more. For individuals who are pregnant, immuno-suppressed
or allergic to eggs, the yellow fever vaccination may not be recommended.
In Canada, the vaccination is available only at designated Yellow
Fever Centres.
Individuals who receive the yellow fever vaccine are provided with an International
Certificate of Vaccination as proof that they have been vaccinated
against yellow fever.
International Health Regulations
Under the World Health Organization's International Health Regulations,
a yellow fever vaccination certificate (i.e., International Certificate
of Vaccination) may be required during international travel at border
crossings. Some countries require all arriving travellers to show proof of
yellow fever vaccination, while other countries require some travellers arriving
or in transit from countries where yellow fever occurs to show proof of vaccination.
In order for the International Certificate of Vaccination for yellow
fever to be considered valid, it must indicate that the individual was vaccinated
at least 10 days prior to the date of entry to the country that requires proof
of vaccination. As mentioned above, it takes 10 days for the vaccine to become
protective.
Countries requiring the International Certificate of Vaccination
for yellow fever are listed in the tables below.

Table
2: Countries requiring proof of yellow fever vaccination from
all travellers |
Benin
Burkina Faso
Cameroon
Central African
Republic
Congo |
Côte d'Ivoire
Democratic Republic
of the Congo
(formerly Zaire)
French Guiana
Gabon
Ghana
|
Liberia
Mali
Niger
Rwanda
Sao Tome and
Principe
Togo |
Source: International Travel and Health, 2000, World
Health Organization |

Table 3: Countries requiring proof of yellow fever
vaccination from some travellers (those arriving from, or having
been in transit through, areas where yellow fever occurs) |
Afghanistan
Albania
Algeria
American Samoa
Angola
Antigua and
Barbuda
Australia
Bahamas
Bangladesh
Barbados
Belize
Bhutan
Bolivia
Brazil
Brunei
Burundi
Cambodia
Cape Verde
China
Christmas Island
Djibouti
Dominica
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Ethiopia
Fiji
French Polynesia
Gambia
Greece
Grenada
Guadeloupe
Guatemala
Guinea
Guinea-Bissau
Guyana |
Haiti
Honduras
India
Indonesia
Iraq
Jamaica
Jordan
Kazakhstan
Kenya
Kiribati
Laos
Lebanon
Lesotho
Libya
Madagascar
Malawi
Malaysia
Maldives
Malta
Mauritania
Mauritius
Mexico
Mozambique
Myanmar
(formerly Burma)
Namibia
Nauru
Nepal
Netherlands
Antilles
New Caledonia and
Dependencies
Nicaragua
Nigeria
Niue
Oman
Pakistan
Palau |
Papua New
Guinea
Paraguay
Peru
Philippines
Pitcairn
Portugal
Reunion
Saint Helena
Saint Kitts and
Nevis
Saint Lucia
Saint Vincent an
the Grenadines
Samoa
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Solomon Islands
Somalia
South Africa
Sri Lanka
Sudan
Suriname
Swaziland
Syria
Tanzania
Thailand
Tonga
Trinidad and
Tobago
Tunisia
Uganda
Viet Nam
Yemen
Zimbabwe |
Source: International Travel and Health, 2000, World
Health Organization |
Prevention and personal precautions |

|
Vaccination is the single most important measure for preventing yellow fever.
Mosquito-control precautions will decrease the risk of exposure to the yellow fever virus. |
Vaccination
The Public Health Agency of Canada strongly recommends travellers
obtain an individual risk assessment with a travel medicine physician
to determine both their risk of exposure to yellow fever and their need
for official proof of vaccination as determined by their travel itinerary.
Mosquito-control precautions
Taking the following personal precautions may reduce the risk
of exposure to day-time biting mosquitoes:
- remain in well-screened or completely enclosed, air-conditioned areas;
- wear light-coloured clothing with full-length pant legs and sleeves;
and
- use insect repellent on exposed skin.
The use of insect repellent on exposed skin is strongly recommended. Of the
insect repellents registered in Canada, those containing 'N, N diethyl-m-toluamide'
(DEET) are the most effective. Although the concentration of DEET varies
from product to product, repellency rates are largely equivalent. In general,
higher concentrations protect for longer periods of time, but there is little
advantage in the duration of repellence with DEET concentrations greater
than 50%, and there may be additional risk of toxicity with higher concentrations.
New micro-encapsulated products containing 33% DEET are registered in Canada,
and they should provide up to 8 hours of protection.
Children and DEET
In rare instances, application of insect repellents with DEET
has been associated with seizures in young children (only 14 cases over
30 years of DEET use and billions of applications every year). The actual
concentration of DEET varies among repellents and can be as high as 95%.
However, repellents with DEET concentrations of 10% are very effective
and should last 3 to 4 hours. Therefore, for children, DEET in a concentration
of 10% or less should be applied sparingly to exposed surfaces only and
washed off after children come indoors.
The likelihood of adverse reactions can be minimized by the following
precautions:
- apply repellent sparingly and only to exposed skin;
- avoid applying high concentration products;
- avoid applying repellents to portions of children's hands that are
likely to contact the eyes or mouth;
- never use repellents on wounds or irritated skin; and
- wash repellent-treated skin after children come indoors. If a reaction
to insect repellent is suspected, wash treated skin and seek medical
attention.
In Canada, DEET products are not recommended for use in children less than
2 years of age. For more
information on insecticide use, go to: Safety Tips on Using Personal Insect Repellent .
Some things to think about... |

|
While yellow fever is rare in travellers, some unvaccinated travellers
have died from this disease. Serious delays - and serious health risks -
can result if a traveller arrives in some countries without official proof
of vaccination. Remember: yellow fever vaccination, when required, must
be obtained at least 10 days before departure.
For more information...
- The Travel Immunization Record is a practical
booklet that helps you keep track of routine and specialized immunizations.
To find out how to order a Travel Immunization Record (cost:
$3.50 plus tax, shipping & handling), contact the Health Resources
Centre, Canadian Public Health Association by email at hrccds@cpha.ca or
by phone at 613-725-3769.
|